Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 45.00 [1][6]. Core Insights - The company is expected to return to a growth trajectory starting in 2026, driven by brand strengthening and new product approvals in the collagen segment [6][11]. - In 2025, the company achieved revenue of HKD 55.19 billion, a slight decrease of 0.4% year-on-year, with a net profit attributable to the parent company of HKD 19.15 billion, down 7.1% year-on-year [6][11]. - The board proposed a dividend of HKD 0.539 per share, along with a special dividend of HKD 0.6714 [6]. Financial Performance - Revenue projections for 2026 and 2027 are adjusted to HKD 61.27 billion and HKD 69.88 billion, respectively, reflecting a decrease of 30.2% and 33.2% from previous estimates [11][13]. - The gross profit margin is expected to decline slightly to 79.6% for 2026 and 2027, down by 2 percentage points from previous forecasts [11][13]. - The company’s earnings per share (EPS) for 2026 and 2027 are projected at HKD 1.88 and HKD 2.07, respectively [11][19]. Brand and Product Development - The company continues to strengthen its brands, "可复美" and "可丽金," with a focus on enhancing consumer perception and product matrix [7]. - The revenue from the "可复美" brand in 2025 was HKD 44.7 billion, while "可丽金" generated HKD 9.2 billion, showing a year-on-year growth of 9.1% [7][9]. - New product launches, including collagen-based items, are anticipated to contribute to future growth [6][11]. Sales Channels and Market Expansion - In 2025, direct sales and distribution channels generated revenues of HKD 41.4 billion and HKD 13.8 billion, respectively, with direct sales accounting for 74.9% of total revenue [8]. - The company has expanded its market presence internationally, with products entering retail channels in Singapore, Malaysia, and North America [8]. Profitability and Cost Structure - The company's gross margin for 2025 was reported at 80.3%, a decrease of 1.8 percentage points year-on-year, attributed to changes in product mix [10]. - The selling expense ratio increased to 37.3% in 2025, reflecting ongoing investments in brand building [10][11].

Investment Rating - The industry investment rating is "Positive" [10] Core Insights - The report highlights strong performance in the beauty and personal care sector, particularly in the medical aesthetics and cosmetics segments, with notable revenue growth and profitability in key companies [9][41] - The report emphasizes the importance of emotional consumption and the demand for innovative products that meet consumer needs, particularly in the context of domestic brands gaining market share [44][45] Summary by Sections Market Review - The beauty care index rose by 2.75% in February, outperforming the broader market [15] - In the medical aesthetics sector, companies like Huahan Co. and Pumen Technology saw significant stock price increases, while in cosmetics, Qing Song Co. and Beitaini led the gains [6][25] Medical Aesthetics Performance - Jinbo Bio reported a revenue of 1.595 billion yuan for 2025, a year-on-year increase of 10.57%, but a net profit decline of 11.08% due to increased costs and strategic adjustments [7][31] - Huaxi Bio's revenue for 2025 was 4.217 billion yuan, down 21.49%, while net profit surged by 67.03% due to cost management and strategic realignment [34][34] Cosmetics Performance - The 38 promotional event showcased strong performance for domestic brands, with significant sales figures reported from live streaming channels [8][36] - Upme Co. projected a revenue of 9.1-9.2 billion yuan for 2025, reflecting a growth of 34.0%-35.4%, driven by its successful brand strategy [41][41] Investment Recommendations - The report recommends focusing on high-quality companies in the medical aesthetics and cosmetics sectors that cater to emotional consumption trends, highlighting companies like Meili Tianyuan Medical Health and Aimeike [9][44] - In cosmetics, brands that innovate with emotional value and safe ingredients are favored, with recommendations for companies like Porlaia and Upme Co. [45][46]

Investment Rating - The industry investment rating is "Overweight" [48] Core Insights - The report highlights strong performance in the domestic beauty and medical aesthetics sectors, with notable revenue growth and profit improvements for key companies [4][41] - The report emphasizes the importance of emotional consumption and the demand for innovative products in the beauty industry, particularly among domestic brands [44][45] Summary by Sections Market Review - In February, the beauty care index rose by 2.75%, outperforming the broader market [13] - Notable stock performances included Huahan Co. (+3.4%) and Pumen Technology (+2.5%) in the medical aesthetics sector, while Qingsong Co. (+16.6%) and Beitaini (+12.5%) led in the cosmetics sector [3][18][23] Medical Aesthetics - Jinbo Bio reported a 2025 revenue of 1.595 billion yuan, a 10.57% increase year-on-year, but a net profit decline of 11.08% due to increased R&D and marketing costs [4][29] - Huaxi Bio's revenue fell by 21.49% to 4.217 billion yuan, while net profit surged by 67.03% due to cost management and non-recurring gains [4][32] Cosmetics - The 38 promotional event saw strong sales for domestic brands, with significant performance from brands like Porlaia and Beitaini [5][36] - Upcoming earnings for Shumei Co. are projected to show a revenue increase of 34.0%-35.4% and a net profit growth of 41.9%-44.4% [41] Investment Recommendations - The report recommends focusing on high-quality companies in the medical aesthetics sector that are expanding their market presence, such as Meilitiantian Medical Health and Aimeike [6][44] - In cosmetics, it suggests investing in brands that emphasize emotional value and innovative ingredients, highlighting companies like Porlaia and Shumei Co. [45][47]

Core Viewpoint - The article discusses the rapid decline of exosomes in the consumer market following the 3·15 exposure event, highlighting the need for regulation in the medical beauty and cosmetics industry while also recognizing the scientific value and potential applications of exosome technology [2][6][21]. Summary by Sections Exosome Market Dynamics - After the 3·15 event, exosome-related products were quickly removed from platforms like Xiaoyang and Tmall, indicating a swift shift from hype to scrutiny in the market [2]. - The exosome industry in China showed strong growth, with a market size reaching 2.279 billion yuan in 2024, reflecting a year-on-year increase of 22.72% [20]. Regulatory and Ethical Concerns - The 3·15 exposure revealed various illegal practices surrounding exosome applications, including unauthorized production and misleading marketing claims, which harm consumer rights and violate regulatory standards [4][21]. - The article emphasizes the need for industry regulation to address these market irregularities while also acknowledging the scientific exploration of exosomes as a significant biomedical research direction [6][25]. Scientific Background and Development - Exosomes were initially dismissed as "cellular waste" until significant discoveries in the 1990s and 2000s revealed their role in intercellular communication and immune activation, leading to a surge in research interest [9][10]. - The Nobel Prize awarded in 2013 for discoveries related to vesicle transport mechanisms further propelled exosome research, establishing their importance in drug development [10][13]. Commercialization Challenges - The transition from laboratory research to consumer products is complex and lengthy, often requiring multiple stages of research and regulatory approval [16][18]. - Currently, most exosome projects are still in the application research and technology validation phase, with only a few advancing to clinical trials [19][20]. Future Outlook - The article suggests that the recent exposure may serve as a necessary correction for the industry, allowing for a clearer path for genuine innovation and compliance in the use of exosome technology [23][25]. - It highlights the importance of addressing foundational scientific questions and regulatory compliance to ensure the safe and effective application of exosomes in consumer products [27][28].

Core Insights - The hair transplant industry is undergoing a fundamental shift from a medical procedure to a new aesthetic consumption model, with hair becoming a new entry point for beauty [2][4][10] - The role of doctors is evolving from mere functional executors to integrated roles combining medicine and aesthetics [9][30] Industry Transformation - The focus of the industry has shifted from traditional medical terminology to an aesthetic design language, emphasizing beauty rather than just medical success rates [8][10] - The user demographic has changed significantly, with over 60% of consultations now coming from women, indicating a shift in demand from functional needs to aesthetic desires [14][15] Changing Consumer Behavior - Women are not just new users; they represent a new demand for beauty enhancement rather than merely addressing hair loss [16][18] - The perception of beauty is expanding to include hairline aesthetics and head-to-face proportions, which can now be designed rather than being seen as natural limitations [20][25] Business Model Redefinition - The industry is moving from a problem-solving market to an aesthetic-driven market, emphasizing style, design, and consistency over technical success rates [31][44] - The transformation includes expanding the user base, lowering decision-making barriers, increasing repeat purchases, and enhancing social media shareability [34][35][37][41] Strategic Implications - The introduction of female-targeted strategies is not merely about expanding the customer base but redefining the entire market approach to hair transplants [32][44] - The shift towards aesthetic services combined with medical delivery is expected to change the competitive landscape of the industry [30][31]

Group 1 - The beauty and personal care sector has shown a slight decline of 0.4% since the beginning of 2026, with significant stock performance variation among key players, ranging from -27.3% to 35.6% [4][12] - The cosmetics market is characterized by intense competition, with domestic brands making significant advancements in R&D and distribution, while international brands are adapting with localized products and flexible marketing strategies [4][20] - The medical beauty sector is witnessing a surge in new products and innovations, with a focus on affordable and specialized offerings, positioning domestic companies to compete effectively against foreign counterparts [4][48] Group 2 - The e-commerce operation segment is undergoing a transformation, with companies like RuYuchen and YiWangYiChuang leveraging self-owned brands and AI to create new growth trajectories [4][43] - Key recommendations for investment include brands with strong channel and product matrices such as MaoGePing and ShangMei, as well as companies like AiMeiKe and LangZi in the medical beauty space [4][45] - The report emphasizes the importance of promotional events like 618 and Double 11, which are critical for brand visibility and sales growth in the competitive online landscape [4][37] Group 3 - The skincare and makeup market is expected to enter a consolidation phase, with strong brands likely to thrive while weaker ones may struggle, particularly in segments like fragrance and hair care [20][21] - Domestic brands are increasingly capturing market share from international brands, with a notable decline in the latter's market presence over recent years [22][27] - The report highlights the strategic importance of product innovation and family series development, as seen with brands like Peiliya, which successfully extend their product lines to enhance sales [28][30]

Core Viewpoint - The article highlights the increasing sophistication of fraudulent businesses that disguise scams under the guise of "new consumption" and "new technology," exploiting regulatory gray areas and consumer trust [2][3]. Group 1: Consumer Fraud Trends - In 2026, consumer spending contributed 52% to economic growth, with total retail sales exceeding 50 trillion yuan, yet fraudulent practices continue to erode consumer trust [2]. - The 315 Gala revealed various scams, including toxic chicken feet sold at 15 yuan for 500 grams, which violate industry cost norms and involve dangerous production practices [5][7]. - A complete black industrial chain is identified, where illegal production and sales persist despite over 6 million inspections annually, indicating a severe imbalance between illegal profits and penalties [7][8]. Group 2: Specific Scams and Techniques - The medical beauty and height-increasing scams exploit consumer anxieties, using misleading claims and unproven products to extract significant fees from vulnerable individuals [9][10]. - Private domain marketing has intensified the exploitation of consumer fears, with companies selling ordinary drugs at inflated prices by falsely branding them as advanced therapies [10]. - The use of AI for generating fake reviews and misleading product recommendations marks a new era of consumer fraud, where trust in AI is manipulated to create a closed loop of misinformation [12]. Group 3: Regulatory Challenges - Traditional industries are adapting to new regulations by exploiting loopholes, as seen in the electric bicycle rental sector, where vehicles exceed safety standards while being marketed as compliant [13]. - The article emphasizes the need for a comprehensive regulatory framework that addresses the entire production, distribution, and sales chain to effectively combat these fraudulent practices [8][14]. - The 315 Gala's enforcement actions are seen as temporary measures, with a call for ongoing regulatory vigilance rather than sporadic crackdowns [13][14].

Core Viewpoint - The article highlights the regulatory chaos surrounding "exosomes" in the medical beauty industry, revealing issues such as unauthorized certifications, false advertising, and illegal injections, which pose risks to consumer safety and market integrity [2][3][4]. Regulatory Issues - Multiple companies have been accused of using medical device licenses to produce exosome products, some of which falsely claim to treat conditions like epilepsy and diabetes, but are actually "three-no products" (no approval, no production, no quality guarantee) [2][4]. - The regulatory framework for exosomes is still being developed, with no exosome drugs approved for market as of March 15, 2026, despite the rapid market growth [4][5]. Market Trends - The incident reflects a deeper transformation in the beauty and medical aesthetics industry, where concepts from medical and biotechnology fields are rapidly entering the consumer market, leading to potential risks as technology outpaces regulation [4][5][6]. - The blending of medical beauty and lifestyle beauty is accelerating, with a growing number of medical concepts being marketed as skincare solutions, raising concerns about consumer safety and product efficacy [5][13]. Consumer Trust and Regulatory Changes - The March 15 exposé serves as a wake-up call for the industry, emphasizing the need for regulatory, scientific, and compliance systems to keep pace with evolving technology narratives [5][19]. - As the regulatory landscape tightens, the beauty industry is shifting towards a focus on trust, with consumers becoming more discerning about product claims and safety [5][19][22]. Data Insights - In recent years, the number of non-compliant cosmetic products has decreased significantly, with the number of problematic batches dropping from 601 in 2023 to 324 in 2025, indicating improved regulatory enforcement [15][17]. - Despite the reduction in regulatory issues, consumer complaints regarding false advertising and product quality have surged, suggesting a shift in consumer focus towards trust and transparency [18][19]. E-commerce and Marketing Regulations - New regulations in 2026 clarify the responsibilities of platforms, operators, and influencers in live commerce, aiming to combat false advertising and ensure consumer protection [26][27]. - The introduction of strict guidelines for live commerce and private domain marketing indicates a move towards greater accountability in the beauty industry [26][29]. Medical Aesthetics and Compliance - The medical aesthetics sector is facing increased scrutiny, with regulations prohibiting unlicensed institutions from performing medical procedures and requiring traceability for medical devices [29][30]. - The challenges posed by unregulated "black technology" in medical aesthetics highlight the need for robust regulatory frameworks to ensure consumer safety [30][31].

Core Viewpoint - The article discusses the rising interest and regulatory challenges surrounding exosomes, a substance claimed to have anti-aging effects, which has not yet received approval for medical use in China [3][5]. Group 1: Regulatory Environment - The National Medical Products Administration in China has issued a draft for public consultation regarding the regulation of exosomes, which are still in the research phase and have not been approved for sale [3][5]. - There are concerns about the illegal use of exosomes in products, with some companies using improper certifications to market these substances, violating medical device regulations [5][6]. Group 2: Market Dynamics - Despite the lack of approved exosome products, companies like New Oxygen have previously launched related aesthetic medical products, although they have since been taken down [5]. - The consumer medical market is booming, prompting some CDMO manufacturers, originally focused on cell and gene therapy, to explore exosome-related businesses [6][7]. Group 3: Safety and Clinical Research - Experts warn about the safety of using exosomes in humans without proper regulatory approval, emphasizing the need for rigorous preclinical and clinical studies to validate safety and efficacy [7][8]. - Approximately 300 clinical trials related to exosomes are currently underway in China, with over 70 new studies registered in the past year, targeting various conditions such as sensitive skin diseases, arthritis, and hair loss [7].

Market Overview - On March 16, 2026, A-shares experienced fluctuations around the previous day's closing position, with all three major indices closing down, each declining by less than 1%[1] - The total trading volume in the Shanghai and Shenzhen markets reached 2.42 trillion yuan, a decrease of over 430 billion yuan compared to March 12[1] - Only a few sectors, including food and beverage, construction, banking, and real estate, saw gains, while the majority of sectors declined[1] Sector Performance - Energy-related sectors such as chemicals, wind power, and lithium batteries showed resilience, supporting the market amid a weak overall performance[1] - Technology sectors (computing power, AI) and non-ferrous metals collectively retreated, negatively impacting the indices[1] - Approximately 1,500 stocks rose, with the proportion of rising stocks close to 30%, remaining stable compared to March 12[1] Investment Insights - The market's recent pullback confirms a weak market effect, prompting a defensive investment style among market participants due to geopolitical tensions and energy price fluctuations[1] - Investors are advised to focus on energy-related sectors, blue-chip stocks, and the pharmaceutical sector for potential opportunities[1] Fund Flow - On March 13, the Shanghai Composite Index saw a net outflow of 3.668 billion yuan, while the Shenzhen Composite Index experienced a net inflow of 6.444 billion yuan[5] - The top three sectors for net inflow were infrastructure, batteries, and agricultural chemicals, while IT services, software development, and consumer electronics faced the largest outflows[5] Private Fund Performance - As of the end of February 2026, the average return of private equity funds reached 6.89%, with 85.04% of the 12,270 products achieving positive returns[15]